ADMA Biologics has been hit with a federal securities class action lawsuit alleging the company inflated its revenue figures. The lawsuit creates binary legal risk for a stock that had been riding strong fundamental momentum, setting up a contested setup between litigation overhang and genuine business performance.
ADMA's reported $510.2M in FY revenue with 57.4% gross margins and positive net income suggest an operationally sound business, and if the lawsuit lacks substantive evidence of actual manipulation, the stock could re-rate back toward pre-lawsuit levels once legal noise fades.
Securities fraud suits alleging revenue inflation have historically preceded restatements in a meaningful minority of cases, and even a partial restatement of ADMA's 19.6% YoY growth story would materially reset consensus estimates and valuation.